Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2018-08-02 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
使用闲置自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhengzhou Antu Bioengineering Co., Ltd. regarding the use of idle self-owned funds for cash management, including details about the investment amount, types, duration, risk control measures, and independent director opinions. It is a formal disclosure about the company's financing activity related to cash management and investment of idle funds, but it does not contain financial statements or detailed financial results. The document length is 1857 characters, which is relatively short and focused on a specific financing-related announcement. This fits the category of Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the appropriate classification is CAP with high confidence.
2018-08-02 Chinese
第二届董事会第二十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 20th meeting of the second board of directors of Zhengzhou Antu Bioengineering Co., Ltd. It details the meeting's convening, voting results, and references to related reports published elsewhere (on the Shanghai Stock Exchange website). The document does not contain the actual reports or financial data but announces board decisions and meeting outcomes. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board. The document length is short (1227 characters), and it is not a full report or financial statement. Therefore, the classification is MANG with high confidence.
2018-08-02 Chinese
使用闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding the use of idle raised funds for cash management. It details the board's approval, the amount of funds involved, types of financial products for investment, risk control measures, and opinions from independent directors, the supervisory board, and the sponsor institution. The document does not contain financial statements or detailed financial results but is a formal disclosure about the company's financing activities related to the use of idle raised funds. It is not a full financial report, earnings release, or management discussion. It fits the category of Capital/Financing Update (CAP) as it updates on the company's use of raised capital for cash management purposes.
2018-08-02 Chinese
使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of cash management using idle funds. It details the company's purchase and management of various financial products such as open-ended wealth management products, structured deposits, and fund purchases, including amounts, dates, and returns. The document is relatively short (2048 characters) and focuses on updates about financing activities related to the company's capital management. There is no indication that this is a full financial report, audit, or earnings release. It is not a regulatory certification or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it provides updates on the company's financing activities and capital usage.
2018-08-01 Chinese
使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a progress announcement regarding the company's use of idle raised funds for cash management, detailing purchases and redemptions of financial products such as bank wealth management products and structured deposits. It includes specific transaction dates, amounts, and yields but does not contain comprehensive financial statements or analysis typical of financial reports. The document is relatively short (2177 characters) and serves as an update on financing activities related to idle raised funds. This fits the definition of a Capital/Financing Update (CAP) rather than a full financial report or regulatory filing. Therefore, the appropriate classification is CAP.
2018-08-01 Chinese
关于全资子公司完成医疗器械生产许可证变更登记的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of a change in the medical device production license for a wholly-owned subsidiary. It details the addition of a new product to the production license and discusses its potential impact and risks. The document is short (764 characters) and is an announcement of a regulatory approval related to product licensing, not a financial report or detailed management discussion. It does not contain financial data, earnings, or detailed report content. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2018-07-09 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.